DrugPatentWatch Database Preview

Details for Patent: 9,079,912

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,079,912 protect, and when does it expire?

Patent 9,079,912 protects JAKAFI and is included in one NDA.

This patent has one hundred and fifty-one patent family members in thirty-four countries.

Summary for Patent: 9,079,912

Title:	Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors
Abstract:	The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
Inventor(s):	Rodgers; James D. (Landenberg, PA), Shepard; Stacey (Wilmington, DE)
Assignee:	Incyte Corporation (Wilmington, DE)
Application Number:	14/274,948
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,079,912
Patent Claim Types: see list of patent claims	Use;

Recent additions to Drugs Protected by US Patent 9,079,912

These patents are from the daily update and have not yet been integrated into the regular database

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Type	RLD	Patent No.	Product	Substance	Delist Req.	Patent Expiration	Usecode	Patented / Exclusive Use
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET	202192	Nov 16, 2011	RX	Yes						U-3226	FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET	202192	Nov 16, 2011	RX	Yes						U-3227	FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET	202192	Nov 16, 2011	RX	Yes						U-3228	FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA

Drugs Protected by US Patent 9,079,912

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192-001	Nov 16, 2011		RX	Yes	No						USE OF RUXOLITINIB (JAKAFI) FOR INHIBITING JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2.
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192-001	Nov 16, 2011		RX	Yes	No						USE OF RUXOLITINIB (JAKAFI) FOR BLOCKING SIGNAL TRANSDUCTION OF JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192-002	Nov 16, 2011		RX	Yes	No						USE OF RUXOLITINIB (JAKAFI) FOR BLOCKING SIGNAL TRANSDUCTION OF JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2

International Family Members for US Patent 9,079,912

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	057995
Austria	525374
Australia	2006326548